Polygenic Score for Clinicopathologic Features and Survival Outcomes in Papillary Thyroid Carcinoma

被引:0
|
作者
Li, Sophie [1 ,2 ]
Zheng, Guibin [1 ]
Xu, Li [1 ]
Goswami, Maitrayee [1 ]
Zafereo, Mark E. [1 ]
Sherman, Steven I. [3 ]
Li, Guojun [1 ]
Sturgis, Erich M. [4 ]
Wang, Jennifer R. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, 1515 Holcombe Blvd, Houston, TX 77030 USA
[2] Baylor Coll Med, Sch Med, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disorders, Houston, TX USA
[4] Baylor Coll Med, Dept Otolaryngol Head & Neck Surg, Houston, TX USA
关键词
BRAF MUTATION; CANCER-RISK; PREVALENCE; VARIANTS; GERMLINE;
D O I
10.1001/jamaoto.2024.3963
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Importance Genome-wide association studies have identified germline variants associated with the development of papillary thyroid carcinoma (PTC) that can be used to construct a polygenic score (PGS). It is important to determine whether patients with higher germline genetic risk, as summarized using PGS, present with more aggressive disease and/or develop worse clinical outcomes. Objective To assess whether germline risk defined by PGS is associated with clinicopathologic features and survival outcomes for patients with PTC. Design, Setting, and Participants This retrospective cohort study included patients with newly diagnosed PTC who presented to The University of Texas MD Anderson Cancer Center for treatment between 1999 and 2014, with a median follow-up of 12 years. Data were analyzed from December 2023 to April 2024. Exposure Germline risk, as defined by PGS. Main Outcomes and Measures Genomic DNA was extracted from buffy coat cells isolated from peripheral blood samples, and genotyping for germline polymorphisms was performed. Germline risk for PTC was estimated with a previously validated PGS calculated from 10 single-nucleotide variations identified through genome-wide association studies. Stage; PTC-specific survival, defined as the time from PTC diagnosis to death caused by PTC; and overall survival, defined as the time from PTC diagnosis to death by any cause, were analyzed. Results A total of 366 patients were included in the study (261 women [71.3%]; mean [SD] age at diagnosis, 44.3 [13.8] years). There was a statistically significant association between higher PGS and multifocality (beta [SE], 0.40 [0.23]; P = .045) and cervical lymph node involvement (N stage) (beta [SE], 0.62 [0.35]; P = .009) at diagnosis. PGS was associated with PTC-specific survival (hazard ratio, 2.66; 95% CI, 1.03-6.85; P = .04), but this association was not independent of age and overall stage. There was not a statistically significant association between PGS and overall survival. Conclusions and Relevance Findings of this cohort study suggest that patients with a higher germline risk of PTC, as estimated by PGS, present with more aggressive clinicopathologic features. These results contribute to the current understanding of inherited risk in PTC and how germline variants could potentially contribute to disease presentation and clinical outcomes.
引用
收藏
页码:113 / 120
页数:8
相关论文
共 50 条
  • [1] Association of Polygenic Score With Tumor Molecular Subtypes in Papillary Thyroid Carcinoma
    Wang, Jennifer R.
    Zafereo, Mark E.
    Wang, Wenyi
    Joshu, Corinne
    Ray, Debashree
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024, 109 (01) : E306 - E313
  • [2] Influence of Body Mass Index on the Clinicopathologic Features of Papillary Thyroid Carcinoma
    Feng, Jia-Wei
    Yang, Xing-Hai
    Wu, Bao-Qiang
    Sun, Dong-Lin
    Jiang, Yong
    Qu, Zhen
    ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY, 2019, 128 (07) : 625 - 632
  • [3] Clinicopathologic features and prognostic factors of tall cell variant of papillary thyroid carcinoma: comparison with classic variant of papillary thyroid carcinoma
    Okuyucu, Kursat
    Alagoz, Engin
    Arslan, Nuri
    Emer, Ozdes
    Ince, Semra
    Deveci, Salih
    Ayan, Asli
    Taslipinar, Abdullah
    Gunalp, Bengul
    Azal, Omer
    NUCLEAR MEDICINE COMMUNICATIONS, 2015, 36 (10) : 1021 - 1025
  • [4] Tall cell variant of papillary thyroid carcinoma: current evidence on clinicopathologic features and molecular biology
    Wang, Xiaofei
    Cheng, Wenli
    Liu, Chongqing
    Li, Jingdong
    ONCOTARGET, 2016, 7 (26) : 40792 - 40799
  • [5] The tall cell variant of papillary thyroid carcinoma: Clinical and pathological features and outcomes
    Regalbuto, C.
    Malandrino, P.
    Frasca, F.
    Pellegriti, G.
    Le Moli, R.
    Vigneri, R.
    Pezzino, V.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2013, 36 (04): : 249 - 254
  • [6] Clinicopathologic Features of Familial Nonmedullary Thyroid Carcinoma
    Fan, Yu-Fang
    Zhang, Bo
    Yang, Xiao
    Shang, Zhong-Hua
    Liu, Hong-Feng
    Xie, Yong
    Liu, Yue-Wu
    Gao, Wei-Sheng
    Wu, Qiong
    Li, Xiao-Yi
    CHINESE MEDICAL JOURNAL, 2015, 128 (08) : 1037 - 1041
  • [7] Comparison of the clinicopathological features and oncologic outcomes of the classic papillary thyroid carcinoma with tall cell features and tall cell variant
    Kim, Kwangsoon
    Jung, Chan Kwon
    Lim, Dong-Jun
    Bae, Ja Seong
    Kim, Jeong Soo
    GLAND SURGERY, 2022, 11 (01) : 56 - 66
  • [8] Clinicopathologic characteristics of familial versus sporadic papillary thyroid carcinoma
    Jiwang, L.
    Zhendong, L.
    Shuchun, L.
    Bo, H.
    Yanguo, L.
    ACTA OTORHINOLARYNGOLOGICA ITALICA, 2015, 35 (04) : 234 - 242
  • [9] The clinicopathologic characteristics of familial and sporadic papillary thyroid carcinoma in Turkish patients
    Sezer, Havva
    Demirkol, Mehmet Onur
    Yazici, Dilek
    Kapran, Yersu
    Alagol, Faruk
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2020, 50 (02) : 360 - 368
  • [10] Clinicopathological features of papillary thyroid carcinoma in HIV-infected patients
    Liu, Jia
    Wu, Deqian
    Zhu, Jinxin
    Dong, Su
    FRONTIERS IN ONCOLOGY, 2023, 13